Mouse OPG ELISA Kit
RayBio® Mouse Osteoprotegerin (TNFRSF11B) ELISA Kit for cell culture supernatants, plasma, and serum samples.
Lead time: Typically ships within 1-2 business days. No Friday shipments.
Product Description
Specifications
Size | 1 Plate Kit, 2 Plate Kit, 5 Plate Kit |
---|---|
Species | Mouse |
Accession Number | O08712 |
Gene Id | 18383 |
Gene Symbols | TNFRSF11B|OCIF|OPG |
Protein Name / Synonyms | Tumor necrosis factor receptor superfamily member 11B (Osteoclastogenesis inhibitory factor) (Osteoprotegerin) |
Quantitative/Semi-Quantitative | Quantitative |
Specificity | This ELISA kit shows no cross-reactivity with the following cytokines tested: Mouse CD30, L CD30, T CD40, CRG-2, CTACK, CXCL16, Eotaxin , Eotaxin-2, Fas Ligand, Fractalkine, GCSF, GM-CFS, IFN- gamma, IGFBP-3, IGFBP-5, IGFBP-6, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-3 Rb, IL-4, IL-5, IL-9, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-17, KC, Leptin R, LEPTIN(OB), LIX, L-Selectin, Lymphotactin, MCP-1, MCP- 5, M-CSF, MIG, MIP-1 alpha, MIP-1 gamma, MIP-2, MIP-3 beta, MIP-3 alpha, PF-4, PSelectin, RANTES, SCF, SDF-1 alpha, TARC, TCA-3, TECK, TIMP-1, TNF-alpha, TNF RI, TNF RII, TPO, VCAM-1, VEGF. |
Compatible Sample Types | Cell Culture Supernatants, Plasma, Serum |
Solid Support | 96-well Microplate |
Method Of Detection | Colorimetric |
Design Principle | Sandwich-based |
Sensitivity | 1 pg/ml Need more sensitivity? Check out the new BIQ-ELISAâ„¢ kit for this target. Still not enough? Then your answer is our Ultrasensitive Biomarker Testing Service powered by Simoa™ technology. |
Detection Range | 1 pg/ml - 1200 pg/ml |
Recommended Dilution (Serum/Plasma) | 20 - 200 fold |
Estimated Lead Time | 1-2 business days |
Shipping Type | Blue ice |
Storage | ≤-20°C |
Risk-Free Guarantee
We offer a 100% guarantee on all ELISA kits and membrane cytokine arrays.
Learn MoreAmazon Gift Cards!
$5 Amazon gift card in every kit box purchased.
Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, et al. Systemic Osteoprotegerin Gene Therapy Restores Tumor-induced Bone Loss in a Therapeutic Model of Breast Cancer Bone Metastasis. Mol Therap. 2008;16(5):871-878. doi:10.1038/mt.2008.48
Carbonneau, C., Despars, G. et al. Heterotopic bone formation derived from multipotent stromal cells is not inhibited in aged mice. Cytotherapy 2014. Epub Ahead of Print. DOI: 10.1016/j.jcyt.2014.03.004
Fradet, Anaïs, et al. "Dual function of ERR? in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin." Cancer research 71.17 (2011): 5728-5738.
Celik M., Gur A., Akdag Z., et al. The effects of long-term exposure to extremely low-frequency magnetic fields on bone formation in ovariectomized rats. Bioelectromagnetics. 2012 Oct;33(7):543-9. doi: 10.1002/bem.21725.
Hartwich JE, Orr WS, Ng CY, et al. Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model. J Pediatr Surg. 2013 Jan;48(1):47-55.
Hinenoya H, Katsuyama H, Nohno T. Genistein affects osteoblastic MC3T3-E1 cells both through estrogen receptor and BMP-Smad signaling pathways. Kawasaki Med J. 2013;39(1):21-31.
-
Great productmouse plasma using 20 fold dilution all samples within range
from MUSC,
on